Judge puts freeze on Merz bid to challenge Botox
US District Court Judge Andrew Guilford slammed the breaks on Merz's foray into a market dominated by Botox, siding with Allergan in a case about stealing intellectual property and poaching sales reps.
View ArticleHologic, seeking rights to Makena, trades barbs with KV
Hologic alleges KV has botched the marketing and wants rights to the drug. KV disagrees.
View ArticlePharma execs: MLR teams are friendlier on digital
Pharma's med/legal/regulatory (MLR) teams, managers of risk and so often the scapegoats for creating roadblocks to digital innovation, were discussed in a much friendlier light by digital marketers at...
View ArticleFor Forest, one Bystolic test down, six to go
Forest Labs may have settled a patent challenge from generics maker Hetero, but the drugmaker has yet to come to terms with six others.
View ArticleCourt says off-label decision against Jazz rep ran afoul of free speech...
A federal appeals court has overturned the conviction of a drug rep for detailing a drug off-label on First Amendment grounds, ordering the lower court to retry the case.
View ArticleFDA regulatory policy chief to take on compounding question
FDA's Jane Axelrad is leaving the Office of Regulatory Policy to head the agency's compounding policy rethink.
View ArticleAmgen pleads guilty, takes CIA in $762 million False Claims Act case
Amgen "marketed the spread" between the price practices pay for Aranesp and that patients pay as a means of driving sales—to the point of having speakers tell docs that they could make a million more...
View ArticleCourt could punt "Pay for Delay" back to Congress
Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called "pay for delay" settlements hangs in the balance.
View ArticleMyriad decision could be a drag on personalized medicine R&D
After a skeptical Supreme Court hearing, diagnostics and biopharma patent lawyers are sweating the outcome of Association for Molecular Pathology vs. Myriad Genetics, in which the Court could decide...
View ArticleNovartis sued for alleged speaker-program abuse
The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.
View ArticleTeva, Pfizer settle on Viagra generic date
Teva said a settlement will allow it to sell a copy of the blockbuster ED pill prior to the official LOE.
View ArticleNovo sued over generic Prandin claim
Three drug purchasing companies have taken the Denmark drugmaker to court in the US. The charge: wrongfully keeping generics off the market.
View ArticleLidoderm reps inflated drug's uses
Endo settled off-label charges for $192 million, resolving civil "whistleblower" suits filed by two sales reps and a physician.
View ArticlePfizer settles off-label Rapamune case for $35M
The drugmaker will dole out $35 million in a deal with 41 state attorneys general after a New York County Supreme Court judge said Wyeth allegedly promoted the immuno-suppressive drug improperly.
View ArticleFive things for pharma marketers to know: Wednesday, November 19
Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.
View ArticleUnsealed court documents shed light on opioid marketing
Drug makers favor big spending on speakers' events and doctor outreach.
View ArticleFive things for pharma marketers to know: Thursday, November 20
CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.
View ArticleVancouver tests prescription heroin
The north-of-the-border solution comes amid climbing heroin abuse in the US.
View ArticleFive things for pharma marketers to know: Tuesday, November 25
AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.
View ArticleFive things for Pharma Marketers to know: Friday, August 29
Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.
View Article
